Integrating Therapeutic Advances and Value-Based Models in Myasthenia Gravis Management

Program Description

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder in which autoantibodies disrupt communication between nerves and muscles. This disruption leads to fluctuating muscle weakness that can severely impair vision, speech, swallowing, and respiratory function. Many patients experience unpredictable cycles of physical decline and fatigue that reduce independence, with approximately 15% of patients remaining refractory to standard treatments and at increased risk of life-threatening myasthenic crises. While traditional management relies on acetylcholinesterase inhibitors, corticosteroids, and non-steroidal immunosuppressants, the therapeutic landscape is shifting toward targeted biologics, including neonatal Fc receptor (FcRn) blockers and complement (C5) inhibitors. These newer therapies offer potentially improved disease control by interrupting key immune pathways, yet their integration is hindered by high costs, complex adverse effect management, and insurance coverage barriers. Managed care pharmacists are pivotal in navigating these challenges by developing utilization management strategies, implementing value-based care models, and coordinating multidisciplinary care to ensure sustainable access to specialty agents. This session features expert-led discussion on the latest clinical data and best practices to assess emerging therapies and apply value-based strategies, empowering managed care professionals to optimize patient-specific treatment decisions and improve long-term clinical and economic outcomes for those living with gMG.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

• Apply knowledge of generalized myasthenia gravis (gMG) clinical features, symptom patterns, and disease burden to guide patient-specific treatment decisions.
• Employ gMG management protocols and emerging therapies to select treatments that target disease-driving mechanisms.
• Examine the economic burden of gMG to implement value-based strategies that guide utilization management of novel therapies.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-084-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Stephanie Iyer, PharmD, CPP, BCACP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: UCB

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Rose Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Katie Naspo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA, has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms